| November 8, 2005 |
| August 28, 2008 |
| March 2003 |
| December 2010 (final data collection date for primary outcome measure) |
| Changes in heart rate and blood pressure [ Time Frame: every 2 minutes during drug infusions and every 10 minutes during the remainder of the study time ] [ Designated as safety issue: No ] |
| Changes in heart rate and blood pressure |
| Complete list of historical versions of study NCT00251602 on ClinicalTrials.gov Archive Site |
| |
| |
| |
| Analysis of Atropine and Propranolol Induced Changes |
| Wavelet Transform and Pharmacodynamic Analysis of Atropine and Propranolol Induced Changes in Human Heart Rate Variability |
The purpose of this study is to learn the effects of genetic make up on response to the drugs atropine and propranolol, to examine how changes in heart rate and blood pressure can be measured, and to test a new statistical analysis method. |
Healthy volunteers will be recruited and screened for eligibility. Participants will be placed into three possible groups based on genetic information obtained during screening. Rolling admissions will continue until at least 10 participants have been recruited for each genetic group. Participants will be randomly assigned to receive either the control (propranolol and saline) or combined drug (propranolol and atropine) treatment in a non-blinded fashion. The participant will return over one week later to receive the alternate treatment. Continuous heart rate/blood pressure data will be recorded until the end of the study period. Respiratory rate will be maintained at a fixed rate. Participants will undergo an orthostasis task, receive the drug or control infusions, and blood samples will then be obtained to determine drug concentrations at specific time intervals. Several relatively new mathematical techniques will be applied to the data. |
| Phase I |
| Interventional |
| Diagnostic, Randomized, Open Label, Active Control, Crossover Assignment, Pharmacokinetics/Dynamics Study |
| Healthy |
- Drug: Atropine
- Drug: Propranolol
- Drug: Normal Saline
|
- Experimental: II ACE genotype
- Experimental: ID ACE genotype
- Experimental: DD ACE genotype
- Placebo Comparator: II ACE genotype
- Placebo Comparator: ID ACE genotype
- Placebo Comparator: DD ACE genotype
|
- Akselrod S, Gordon D, Ubel FA, Shannon DC, Berger AC, Cohen RJ. Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control. Science. 1981 Jul 10;213(4504):220-2.
- Craft N, Schwartz JB. Effects of age on intrinsic heart rate, heart rate variability, and AV conduction in healthy humans. Am J Physiol. 1995 Apr;268(4 Pt 2):H1441-52.
- Pagani M, Lombardi F, Guzzetti S, Rimoldi O, Furlan R, Pizzinelli P, Sandrone G, Malfatto G, Dell'Orto S, Piccaluga E, et al. Power spectral analysis of heart rate and arterial pressure variabilities as a marker of sympatho-vagal interaction in man and conscious dog. Circ Res. 1986 Aug;59(2):178-93.
|
| |
| Active, not recruiting |
| 30 |
| December 2010 |
| December 2010 (final data collection date for primary outcome measure) |
Inclusion Criteria:
- Healthy male and female volunteers
- Ages 21-40
- Body Mass Index >18.0 and <27.0
Exclusion Criteria:
- History of any chronic illnesses including cardiac diseases and bleeding problems
- Drug use of any kind
- Participation in any clinical trial within the last month
- Tobacco use and/or alcohol abuse
- Use of dietary supplements and unwillingness to refrain
|
| Both |
| 21 Years to 40 Years |
| Yes |
| Contact information is only displayed when the study is recruiting subjects |
| United States |
| |
| NCT00251602 |
| Shari Ling, M.D., National Institute on Aging |
| AG0059 |
| National Institute on Aging (NIA) |
|
| Principal Investigator: |
Shari M. Ling, MD |
National Institute on Aging, Clinical Research Branch |
|
|
| National Institute on Aging (NIA) |
| August 2008 |
